Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nazar Golewale

Vascular & Interventional Radiology Merrillville, IN Medical Doctor

NPI 1851548127 CMS profile 175534

8127 Merrillville Rd Ste 1B, Merrillville, IN 46410

Open in the dashboard

General payments

$224,192

101 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nazar Golewale of Merrillville, IN is reported in the CMS Open Payments database as having received $224,192 across 101 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $76,073 28
2024 General $81,779 26
2023 General $60,566 12
2022 General $4,063 14
2021 General $185 6
2020 General $211 6
2019 General $1,316 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nazar Golewale
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Nazar Golewale were reported at $76,073. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Nazar Golewale Vascular & Interventional Radiology median Middle half National median
2019 $1,316 $422 $125–$1,555 $163
2020 $211 $200 $68–$652 $114
2021 $185 $280 $99–$866 $132
2022 $4,063 $433 $137–$1,497 $149
2023 $60,566 $506 $152–$2,019 $160
2024 $81,779 $556 $175–$1,930 $164
2025 $76,073 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $220,879 44 payments
  2. Philips Electronics North America Corporation $664 3 payments
  3. Sirtex Medical Inc $637 2 payments
  4. Nevro Corp. $541 8 payments
  5. Cardiovascular Systems Inc. $320 15 payments
  6. Surgenex LLC $290 5 payments
  7. Biotronik Inc. $149 3 payments
  8. Globus Medical, Inc. $111 4 payments
  9. Organogenesis Inc. $110 2 payments
  10. Sanara MedTech Inc. $106 1 payment
  11. Other $385 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $218,667 10 payments
  2. Food and Beverage $3,947 82 payments
  3. Travel and Lodging $1,579 9 payments
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac Et $143,917 7 payments
  2. Auryon Laser System 100-120 Vac Cv $74,750 3 payments
  3. AURYON LASER SYSTEM 100-120 VAC Pad $1,589 27 payments
  4. SIR-Spheres Microspheres $637 2 payments
  5. IGT D Peripheral $619 1 payment
  6. ALPHAVAC $616 6 payments
  7. Senza $541 8 payments
  8. Peripheral Orbital Atherectomy System $290 13 payments
  9. SurMatrix $290 5 payments
  10. PelloGraft $290 5 payments
  11. Other $2,165 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

569

Median for Diagnostic Radiology: 24

Drug cost

$26,366

Median for Diagnostic Radiology: $190

Branded share of claims

36%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 16 $20,933
Clopidogrel Clopidogrel Bisulfate Brand 149 $1,446
Cilostazol Generic 70 $1,075
Nitro-Bid Nitroglycerin Brand 12 $961
Triamcinolone Acetonide Generic 27 $426
Gabapentin Generic 40 $323
Doxycycline Hyclate Generic 44 $319
Tamsulosin Hcl Generic 23 $153
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 28 $131
Clindamycin Hcl Generic 11 $128

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 92 billing codes

Paid by Medicare

$6,040,837

Of which drugs: $2,745,548

Medicare patients

524

Average age 75

Services billed

6,954

312 women, 212 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Diabetes 59%
Chronic kidney disease 51%
Heart failure 50%
Ischemic heart disease 42%
Atrial fibrillation 38%
Depression 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

101 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record